Cancer Therapy Advisor

Cancer Therapy Advisor
Extended Letrozole Prolonged Survival in Postmenopausal Patients With Breast Cancer

When compared with the standard 2-3 years of letrozole, 5 years of letrozole treatment improved both disease-free survival and overall survival.

Cancer Therapy Advisor
Younger Age at Diagnosis May Predict Higher VTE Risk in Patients With Multiple Myeloma

Among younger patients with multiple myeloma and those with a high white cell count, higher-intensity thromboprophylaxis may be necessary for reducing the risk of venous thromboembolism.

Cancer Therapy Advisor
Keytruda Approved as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

The FDA approves keytruda in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1...

Cancer Therapy Advisor
Neoadjuvant Chemotherapy May Reduce Short-Term Mortality in Advanced Ovarian Cancer

Neoadjuvant chemotherapy may decrease short-term mortality in patients with advanced ovarian cancer, according to recently published research.

Cancer Therapy Advisor
Breast, Prostate Cancer Common in Patients With COVID-19 and Cancer History

Research highlights the importance of protecting patients with cancer while guaranteeing cancer care continuity during the pandemic.

Cancer Therapy Advisor
Robotic-Assisted Radical Cystectomy Safe, Feasible for Octogenarians

Doctors compare mortality rates to find that RARC was associated with lower in-hospital mortality compared with open surgery even after controlling for patient and hospital characteristics.

Cancer Therapy Advisor
Surgery vs Radiation May Lower Risk of Death From High-Risk Prostate Cancer

A new study finds that radical prostatectomy is associated with improved cancer-specific survival compared with external beam radiation therapy among men with high-risk prostate cancer.

Cancer Therapy Advisor
Androgen Signaling Inhibitors Appear More Effective in Luminal mCRPC

Among patients with mCRPC, androgen signaling inhibitors may be more beneficial for patients with luminal tumors than for those with basal tumors.

Cancer Therapy Advisor
Sugemalimab Deemed Effective as Consolidation for Stage III Non–Small-Cell Lung Cancer

Consolidation with sugemalimab improves PFS, compared with placebo, in patients with unresectable, stage III NSCLC who have not progressed after CRT, phase 3 results suggest.

Cancer Therapy Advisor
Prognostic Importance of Extramedullary Lesions in Multiple Myeloma

Researchers conducting a retrospective study identified extramedullary lesions as a possible indicator of poor prognosis in patients with MM treated in the first line with bortezomib. 

Cancer Therapy Advisor
Subscribe to Cancer Therapy Advisor

source list reference

rgb(171, 222, 222)
200, 66, 245
rgb(195, 2, 230)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(242, 0, 137)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb(156, 242, 7)
rgb(224, 4, 129)
rgb(80, 147, 199)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb(217, 7, 192)
rgb(2, 230, 230)